QVT Financial’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-309,431
Closed -$42.3M 52
2020
Q2
$42.3M Buy
309,431
+113,991
+58% +$14.5M 7.19% 4
2020
Q1
$21.1M Buy
195,440
+46,335
+31% +$5.33M 4.91% 7
2019
Q4
$18M Buy
149,105
+64,719
+77% +$7.22M 3.5% 11
2019
Q3
$8.4M Buy
+84,386
New +$8.83M 1.73% 19
2017
Q4
Sell
-372,984
Closed -$41.5M 66
2017
Q3
$41.5M Sell
372,984
-139,527
-27% -$14.9M 1.55% 13
2017
Q2
$53M Sell
512,511
-183,924
-26% -$18.1M 1.41% 10
2017
Q1
$68.1M Buy
696,435
+300,000
+76% +$28.7M 2.11% 8
2016
Q4
$35.1M Buy
396,435
+115,245
+41% +$10.5M 1.07% 14
2016
Q3
$27.1M Buy
281,190
+100,698
+56% +$9.58M 1.02% 16
2016
Q2
$15.5M Hold
180,492
1.07% 29
2016
Q1
$15.7M Sell
180,492
-87,597
-33% -$7.83M 0.96% 31
2015
Q4
$30.2M Buy
268,089
+29,109
+12% +$3.16M 1.7% 11
2015
Q3
$24.2M Buy
238,980
+126,072
+112% +$15.1M 0.83% 19
2015
Q2
$13.9M Buy
+112,908
New +$13.5M 0.21% 48
2015
Q1
Sell
-2,079
Closed -$210K 88
2014
Q4
$210K Buy
+2,079
New +$202K 0.01% 93

Other funds holding IBB

QVT Financial's IBB Position: Q3 2020 in Review

QVT Financial sold out of iShares Biotechnology ETF (IBB) in Q3 2020, closing a stake of 309,431 shares — an estimated $42.3M sold.

QVT Financial first reported a position in IBB in Q4 2014 and held it in 15 quarters. The position peaked at $68.1M in Q1 2017. 784 funds tracked by Wall St. Rank hold IBB as of Q3 2020.

  • QVT Financial reported no remaining iShares Biotechnology ETF position as of Q3 2020 after selling out during the quarter.
  • QVT Financial sold 309,431 iShares Biotechnology ETF shares in Q3 2020, an estimated $42.3M.
  • QVT Financial first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 15 quarters.
  • QVT Financial's iShares Biotechnology ETF position peaked at $68.1M in Q1 2017.
  • 784 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2020.

Based on QVT Financial's 13F filing for Q3 2020, filed 16 Nov 2020.